Skye Bioscience Hit With Securities Class Action Over Nimacimab Disclosures as Firms Court Lead Plaintiff

Overview

• The lawsuit alleges Skye misled investors about the effectiveness of its lead drug candidate, nimacimab, and overstated its clinical, regulatory, and commercial prospects.
• The proposed class covers purchasers of SKYE securities from November 4, 2024 through October 3, 2025.
• Rosen Law Firm, The Schall Law Firm, The Gross Law Firm, and Robbins LLP have issued notices recruiting investors and outlining how to participate or seek leadership of the case.
• Robbins LLP says the complaint cites an October 6, 2025 press release reporting nimacimab monotherapy missed its primary endpoint and showed lower-than-expected exposure, after which the stock fell about 60% to $1.90.
• No class has been certified and the allegations remain unproven, with claims brought under Exchange Act §§10(b), 20(a) and SEC Rule 10b-5.